Utilization of Intravenous Ribavirin Among Reproductive Age Adults in 2010–2017: A Population-Based Study in the Yinzhou District, Ningbo City of China

Hailong Li¹, Houyu Zhao¹, Hongbo Lin², Peng Shen², Cuili Liu³ and Siyan Zhan¹*

¹ Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China, ² Yinzhou District Center for Disease Control and Prevention, Ningbo, China, ³ Center for Drug Revaluation, National Medical Products Administration (NMPA), Beijing, China

Background: Intravenous (IV) ribavirin is not approved in US and European Union, but it is authorized in China. Significant teratogenic and embryocidal effects of ribavirin have been found in almost all animal studies, it is critical to investigate the prevalence and trends of the utilization of IV ribavirin among reproductive age population.

Objective: To evaluate the prevalence and trends of IV ribavirin use among reproductive-age population in 2010–2017.

Methods: The study design of our study is retrospective cross-sectional study based on healthcare database. We identified and extracted the data of residents aged 18–44 years by using Yinzhou healthcare information database at 21 January, 2018. A cohort of IV ribavirin users were identified through outpatient prescription records in 3 general hospitals and 24 community health centers from 2010 to 2017. We reported the number, proportion, and prevalence of the exposure to IV ribavirin stratified by sex, age, marital status, education level, occupation, hospital level, calendar year, diagnosis, and dosage. The overall trends of IV ribavirin use, and the trends in different levels of hospital and common diagnoses were further analyzed and described.

Result: During the study period, the prevalence of IV ribavirin use among reproductive-age adults was 6.02% (48,287/801,667). Relatively higher prevalence were found in adults aged 40–44 (8.04%, 95% CI: 7.90–8.17), unmarried patients (8.91%, 95% CI: 8.74–9.08), and who had more than 9 years of education (6.82%, 95% CI: 6.74–6.90). Compared to secondary and tertiary hospitals, IV ribavirin was more likely to be dispensed in primary hospitals (19.44%, 95% CI: 19.28–19.61). The most common diagnoses were acute upper respiratory infections (AURIs), accounting for 80% of the patients exposed to IV ribavirin. For patients with AURIs, the prevalence of IV ribavirin was nearly 30%. Overall, the prevalence of IV ribavirin use decreased from 1.72% in 2010 to 0.24% in 2017.
INTRODUCTION
Ribavirin is a kind of antiviral drug which has direct antiviral activity in tissue culture against many RNA viruses. Ribavirin increases the mutation frequency in the genomes of several RNA viruses and Ribavirin triphosphate inhibits HCV polymerase in a biochemical reaction (1). Oral ribavirin used in combination with interferon alfa-2b (non-pegylated) for treatment of chronic hepatitis C (CHC) and ribavirin aerosol used for the treatment of severe lower respiratory tract infections due to respiratory syncytial virus (RSV) in children have been approved by the United States Food and Drug Administration (FDA) (1–7). Because lack of evidence proves the efficacy and safety of intravenous (IV) ribavirin, it is not approved in most developed countries and regions (e.g., North America, European Union, and Australia) (2). However, in China, it is authorized for the treatment of patients with pneumonia and bronchitis due to RSV. Human RSV is the major cause of many respiratory tract diseases among infants and young children (8). For adults, a study in China shows that among 9,871 patients who went to the hospital because of acute respiratory infections, only 95 (1%) patients were detected positive for RSV by RT-PCR analysis (9). Moreover, RSV infections in adults are typically mild, transient and do not require hospitalization or antiviral treatment (10, 11). Thus, it is probably inappropriate to prescribe IV ribavirin to adults with acute respiratory infections.

Ribavirin has been assigned to pregnancy category X by the FDA which means that its use is contraindicated in pregnant women. Nearly all animal studies have demonstrated its significant teratogenic and embryocidal effects. In addition, ribavirin has a multiple-dose half-life of 12 days, and so it may persist in non-plasma compartments for as long as 6 months (12, 13). Therefore, female patients receiving ribavirin and the partners of male patients taking ribavirin therapy must avoid pregnancy, using at least two reliable types of contraception, during therapy and at least 6 months after completion of treatment (14, 15). In China, the IV ribavirin instructions clearly state that ribavirin is contraindicated in pregnant women, lactating women, and women who may be pregnant. Therefore, it is at a high risk of using IV ribavirin for men and women in reproductive age.

Despite that IV ribavirin had been approved in China for many years, little is known about the prevalence and trends of its use among adults. Quantifying the use of IV ribavirin among adults in reproductive age is a crucial step toward evaluating its risk-benefit. Thus, we aimed to investigate the utilization of IV ribavirin in adults aged 18–44 years old using Yinzhou healthcare information database from 2010 to 2017 in this observational study.

Conclusion: We found IV ribavirin was mainly used for AURIs which suggested that a large amount of IV ribavirin use was probably inappropriate. The prevalence was decreasing by 87% over the past 8 years, and we encourage clinicians and pharmacists to continually avoid inappropriate use of IV ribavirin.

Keywords: intravenous ribavirin, reproductive age, drug utilization, rational drug use, population-based study

MATERIALS AND METHODS
Data Resources
Yinzhou is a district in Ningbo, an eastern coastal city of China, with nearly 1.5 million residents in 2015. In 2005, the local health authority rolled out a Health Information System, which has collected and administrated the healthcare information of the residents since then. By 2010, this system covered all the hospitals in Yinzhou. Moreover, it integrated electronic medical records (EMRs) of hospitals, public health surveillance and disease management among communities. The administrative healthcare database stored all the data, including outpatient and inpatient records, prescribing information, and general demographic characteristics. The outpatient and inpatient records comprised hospital code, patient code, date of diagnosis, diagnosis name and diagnosis code (10th revision of the International Classification of Diseases and Related Health Problems, ICD-10). Prescribing information consisted of prescription code, prescription date, and product name, brand, generic name, and dosage form and dosage frequency of drugs. All the data from patients was anonymized and no personal details were shared with health researchers for privacy protection. This database has been used and described in previous studies (16–20). This study was approved by the ethical review board of Peking University Health Science Center (IRB00001052-18013). Informed consent was not required owing to the use of anonymized routine data. We extracted the data was at January 21, 2018.

Study Population
The study design of our study is retrospective cross-sectional study based on healthcare database. We first identified the eligible residents by using the health archives in the Yinzhou healthcare information database. The inclusion criteria is the residents aged 18–44 years old who have a high probability to be pregnant or be the partners of pregnant women. We define the residents who met this inclusion criteria as general population. As shown in Figure 1, the residents aged 18–44 years old when they went to the hospital from 2010 to 2017 were included via electronic medical records of 28 hospitals, including 3 general hospitals (2 tertiary hospitals, 1 secondary hospital) and 24 primary healthcare facilities. Furthermore, we excluded the patients who had no prescription records of IV ribavirin during the study period. By using the database, we extracted the information of patients ID, sex, birthday, marital status, education level, occupation, diagnosis code (ICD-10), diagnosis name, hospital level, prescription date, and generic name and dose of drugs.
Statistical Analysis

The number of IV ribavirin prescriptions and the number of patients who had ever exposed to ribavirin were reported among the reproductive age patients. We calculated the overall prevalence and its Wald 95% confidence intervals of IV ribavirin exposure where the denominator was the general population in reproductive age.

Additionally, prevalence estimates for IV ribavirin exposure were calculated, stratified by characteristics including sex, age, marital status, educational level, and occupation. We also investigated the prevalence of IV ribavirin among patients in different levels of hospitals with the numerator reflecting the total number of patients exposed to IV ribavirin in a given level of hospital and the denominator consisting of the total number of patients in the same level of the hospital.

The most common corresponding diagnoses (ICD-10) of IV ribavirin users were reported with a specific prevalence. In this case, the numerator was the number of IV ribavirin users with a given diagnosis and the denominator was the total number of patients with the same diagnosis.

The proportions of IV ribavirin overdose were evaluated for both single dose and daily dose. According to the package inserts of the IV ribavirin (500 mg each time, 2 times per day), we stratified the single dose by 500 mg and the daily dose by 1,000 mg.

Finally, we plotted the trends in the use of IV ribavirin from 2010 to 2017. The year-specific prevalence for IV ribavirin exposure in different hospitals and diagnoses were described. In these estimates, the numerator was the number of IV ribavirin users in a given hospital/with a given diagnosis for each year and the denominator was the total number of patients in the same hospital/with the same diagnosis for a specific year. Furthermore, we conducted a time series analysis to test the change of IV ribavirin use.

RESULTS

As the general population in our study, there were 801,667 residents of reproductive age in Yinzhou from 2010 to 2017. During the study period, our study cohort comprised 48,289 patients aged 18–44 years with at least one prescription record of IV ribavirin. Overall, the prevalence of IV ribavirin was 6.02% (48,287/801,667).

Table 1 provides the baseline characteristic of the general population and patients exposed to IV ribavirin in this study. The numbers of male and female patients who had ever received IV ribavirin were nearly equal, but the prevalence of IV ribavirin was higher among males than that among females (6.33%, 95% CI: 6.25–6.41 vs. 5.75%, 95% CI: 5.68–5.82, \(P < 0.001\)). The prevalence of IV ribavirin (8.04%, 95% CI: 7.90–8.17) was highest in patients aged 40–44 years old \((P < 0.001)\). Approximately 70% of patients of the study cohort were married, followed by 20% unmarried, 10% others. The unmarried patients were the most likely to be treated with IV ribavirin (8.91%, 95% CI: 8.74–9.08, \(P < 0.001\)). Patients with <9 years of education were more likely to be exposed to IV ribavirin compared to patients with more than 9 years of education (6.82%, 95% CI: 6.74–6.90 vs. 5.32%, 95% CI: 5.25–5.39, \(P < 0.001\)). The prevalence of using IV ribavirin were highest (16.93%) among students, followed by 10.15% among farmer, and 9.87% among the unemployed \((P < 0.001)\).

As shown in Table 2, primary hospitals were more likely to dispense IV ribavirin (19.44%, 95% CI: 19.28–19.61, \(P < 0.001\)) than secondary hospitals (14.87%, 95% CI: 14.36–15.40) and tertiary hospitals (10.73%, 95% CI: 10.41–11.05).

The most common diagnosis was acute upper respiratory infections (AURIs), presenting in 80% of diagnosis records of the patients exposed to IV ribavirin (Table 3). Among outpatients whose first diagnosis was AURIs, the prevalence of IV ribavirin was nearly 30%. There were almost 7.23% of IV ribavirin users had other infectious diseases (other and unspecified infectious diseases) as the first diagnosis. The prevalence of IV ribavirin were 25, 24.14, 21.08, 14.80, and 14.52% among patients who had a diagnosis of viral hemorrhagic fevers, other respiratory disorders, other infectious diseases, viral infections characterized by skin and mucous membrane lesions, and fever of other and unknown origin, respectively.

Table 4 demonstrates the numbers and proportions of users and prescriptions in different doses. There were 89,225 prescriptions of IV ribavirin with a single dose \(\leq 500\) mg, accounting for 86% of the total number of IV ribavirin exposure.
The prevalence of IV ribavirin use among reproductive age adults in China was nearly 6% during the study period. IV ribavirin was prescribed to 99.28% of patients (n = 103,274) with daily dose ≤1,000 mg.

**DISCUSSION**

To our knowledge, this is the first study to investigate the prevalence of IV ribavirin use among reproductive age adults in China. We found nearly 6% of residents had at least one prescription of IV ribavirin during the study period. IV ribavirin

---

**TABLE 1** Baseline characteristics of general population and patients exposed to the IV ribavirin.

| Characteristics   | General population | Ribavirin user | Proportion (%) | PR (95% CI)     | $P$   |
|-------------------|--------------------|----------------|----------------|-----------------|------|
| **Sex**           |                    |                |                |                 |      |
| Male              | 378,782            | 23,969         | 49.64          | 6.33 (6.25–6.41) | <0.001|
| Female            | 422,885            | 24,318         | 50.36          | 5.75 (5.68–5.82) |      |
| **Age**           |                    |                |                |                 |      |
| 18–24             | 195,723            | 9,372          | 19.41          | 4.79 (4.69–4.88) | <0.001|
| 25–29             | 152,251            | 9,387          | 19.44          | 6.17 (6.04–6.29) |      |
| 30–34             | 143,073            | 10,800         | 22.37          | 7.55 (7.41–7.69) |      |
| 35–39             | 153,259            | 10,353         | 21.44          | 6.76 (6.63–6.88) |      |
| 40–44             | 157,361            | 12,644         | 26.19          | 8.04 (7.90–8.17) |      |
| **Marital status**|                    |                |                |                 |      |
| Unmarried         | 110,067            | 9,808          | 20.31          | 8.91 (8.74–9.08) | <0.001|
| Married           | 610,331            | 33,765         | 69.93          | 5.53 (5.47–5.59) |      |
| Divorced          | 5,388              | 360            | 0.75           | 6.68 (6.01–7.35) |      |
| Unknown           | 75,881             | 4,354          | 9.02           | 5.74 (5.57–5.90) |      |
| **Education level**|                   |                |                |                 |      |
| <9 years          | 376,322            | 25,666         | 53.15          | 6.82 (6.74–6.90) | <0.001|
| ≥9 years          | 425,345            | 22,621         | 46.85          | 5.32 (5.25–5.39) |      |
| **Occupation**    |                    |                |                |                 |      |
| Workers           | 240,898            | 14,499         | 30.03          | 6.02 (5.92–6.11) | <0.001|
| Students          | 22,250             | 3,766          | 7.80           | 16.93 (16.43–17.42) |      |
| Service staff     | 110,916            | 4,892          | 10.13          | 4.41 (4.29–4.53) |      |
| Civil servant     | 73,367             | 4,522          | 9.36           | 6.16 (5.99–6.34) |      |
| Unemployed        | 29,523             | 2,915          | 6.04           | 9.87 (9.53–10.21) |      |
| Farmer            | 66,220             | 6,724          | 13.93          | 10.15 (9.92–10.38) |      |
| Others            | 189,099            | 7,243          | 15.00          | 3.83 (3.74–3.92) |      |
| Unknown           | 69,394             | 3,726          | 7.72           | 5.37 (5.20–5.54) |      |

Proportion: the denominator was the total number of IV ribavirin users (N = 48,289).
PR, prevalence rate, for which the denominator was the total number of general population.

**TABLE 2** Prevalence of ribavirin users in different level of hospital.

| Hospital level | Total patients | Ribavirin users | Proportion (%) | PR (95% CI)     |
|----------------|----------------|-----------------|----------------|-----------------|
| Primary        | 218,926        | 42,567          | 88.15          | 19.44 (19.28–19.61) |
| Secondary      | 18,155         | 2,700           | 5.59           | 14.87 (14.36–15.40) |
| Tertiary       | 35,872         | 3,848           | 7.97           | 10.73 (10.41–11.05) |

Proportion: the denominator was the total number of IV ribavirin users (N = 48,289).
PR, prevalence rate, where the denominator was the total number of patients in specific level of hospital.

Further, the proportion of prescriptions with daily dose ≤1,000 mg of IV ribavirin was 99.28% (n = 103,274).

**Figure 2** and **Appendix Table 1** reveal the trends of IV ribavirin use among the general population aged 18–44 over the 8 years. The prevalence of IV ribavirin users decreased from 1.72% (95% CI: 1.69–1.74) in 2010 to 0.24% (95% CI: 0.22–0.25) in 2017 ($P < 0.001$). The prevalence of dispensed IV ribavirin decreased sharply from 2010 to 2012 for secondary and tertiary hospitals. Changes of IV ribavirin prevalence among patients and prescriptions are illustrated in **Figure 2** and **Appendix Table 2**.

When stratified by different diagnoses (**Figure 4**), the IV ribavirin prescription prevalence decreased with fluctuation. For AURIs, the prevalence rate of IV ribavirin decreased gradually from 19% in 2010 to 1% in 2017.
TABLE 3 | Prevalence of IV ribavirin users among patients with different diagnoses.

| Diagnosis                                           | All patients | Ribavirin users (%) | PR (%) | 95% CI          |
|-----------------------------------------------------|--------------|---------------------|--------|----------------|
| Acute upper respiratory infections<sup>a</sup>       | 130,079      | 38,424 (29.57)      | 29.54  | 29.29–29.79    |
| Other infectious disease<sup>b</sup>                | 16,568       | 3,491 (21.08)       | 21.08  | 20.48–21.71    |
| Other respiratory disorders<sup>c</sup>             | 8,992        | 2,171 (24.14)       | 24.14  | 23.26–25.04    |
| Other diseases of upper respiratory tract<sup>d</sup>| 37,750       | 1,977 (5.24)        | 5.24   | 5.01–5.47      |
| Disorders of conjunctiva                            | 22,859       | 1,154 (5.05)        | 5.05   | 4.77–5.34      |
| Other acute lower respiratory infections<sup>e</sup>| 17,316       | 1,065 (6.15)        | 6.15   | 5.80–6.52      |
| Viral infections characterized by skin and mucous membrane lesions<sup>f</sup> | 6,884         | 1,019 (14.80)       | 14.80  | 13.97–15.66    |
| Fever of other and unknown origin                   | 5,146        | 747 (14.52)         | 14.52  | 13.56–15.51    |
| Chronic lower respiratory diseases                  | 17,907       | 558 (3.12)          | 3.12   | 2.87–3.38      |
| Keratitis                                           | 8,178        | 264 (3.23)          | 3.23   | 2.86–3.63      |
| Other and unspecified non-infective gastroenteritis and colitis | 24,909       | 140 (0.56)          | 0.56   | 0.47–0.66      |
| Stomatitis and related lesions                      | 7,753        | 78 (1.01)           | 1.01   | 0.80–1.25      |
| Viral hemorrhagic fevers                            | 4            | 1 (0.25)            | 0.25   | 0.18–0.33      |
| Other diagnoses<sup>g</sup>                         | 253,901      | 3,951 (1.56)        | 1.56   | 1.51–1.61      |

PR, prevalence rate, where the denominator was the total number of patients with specific diagnosis.
<sup>a</sup>ICD10: J00–J06, including acute nasopharyngitis (common cold), acute sinusitis, acute pharyngitis, acute tonsillitis, acute laryngitis and tracheitis, acute obstructive laryngitis (croup) and epiglottis and acute upper respiratory infections of multiple and unspecified sites.
<sup>b</sup>ICD10: J09, including other infectious disease, Unspecified infectious disease.
<sup>c</sup>ICD10: J20–J22, other acute lower respiratory infections, acute bronchitis, acute bronchiolitis, unspecified acute lower respiratory infection, etc.
<sup>d</sup>ICD10: J00–J09, including acute nasopharyngitis and pharyngitis, chronic sinusitis, peritonsillar abscess etc.
<sup>e</sup>ICD10: J00–J09, viral infections characterized by skin and mucous membrane lesion, etc.
<sup>f</sup>Including gastritis and duodenitis, dyspepsia, rashes and other non-specific skin eruptions, cough, etc.

TABLE 4 | Proportions of IV ribavirin prescriptions in different doses.

| Dosage (mg) | N   | Proportion (%) | 95% CI          |
|------------|-----|----------------|----------------|
| Single dose|     |                |                |
| ≤500       | 89,225 | 85.78          | 85.56–85.99    |
| >500       | 14,796 | 14.22          | 14.01–14.44    |
| Total      | 104,021 | –              | –              |
| Daily dose |     |                |                |
| ≤1,000     | 103,274 | 99.28          | 99.23–99.33    |
| >1,000     | 747   | 0.72           | 0.67–0.77      |
| Total      | 104,021 | –              | –              |

was commonly used among the residents aged 18–44 years in Yinzhou District during 2010–2017. And studies had raised the concerned about overuse of intravenous therapy in China (21, 22). However, IV ribavirin can only be authorized for patients with life-threatening diseases as an Emergency Investigational New Drug (EIND) applicant in USA. Andrea et al. found that 608 IV ribavirin EIND requests were made for 19 disease conditions from 1997 to 2008 via FDA’s EIND database (2). Clinical outcome and adverse events were deficient in the report of the EIND database, so further analysis of either outcome was not feasible.

The prevalence of exposure to IV ribavirin varied by age, marital status, education level, occupation and hospital level (P < 0.001). Relative high prevalence were found in elder adults, unmarried residents, residents with <9 years of education, students, and farmers and unemployed residents. In addition, primary hospitals dispensed a higher proportion of IV ribavirin. A similar pattern was found in a study in the US, which is to evaluate the prevalence of exposure to antiviral medications during pregnancy in a cohort of pregnant women (23).

Our results manifest that the majority of IV ribavirin use was for AURIs. These results were different from another study, which illustrated a large proportion of IV ribavirin use EIND requests concerned adenovirus infections in immunocompromised patients. Evidence suggests that IV ribavirin may be an alternative treatment for patients with hemorrhagic fever (24, 25). In our study, there were just 4 patients with diagnosis of viral hemorrhagic fevers, whereas only one of them had a prescription of IV ribavirin. In China, treatment for pneumonia and bronchitis due to RSV is the main indication of IV ribavirin. However, a study revealed that only 1% of the patients who sought medical care for acute respiratory infections was detected positive for RSV (9). In our study, only 34 patients were tested for RSV in 2010–2017 and 6 of them were positive. Accordingly, we speculated that a large number of IV ribavirin were misused in China.

A Canadian study indicated that high-dose ribavirin is associated with a high risk of adverse events (26). According to the instruction of the intravenous ribavirin (500 mg each time, 2 times per day), we found that there were <1% of users and prescriptions of IV ribavirin were overdose for daily use. For single dose, there were about 14% of prescriptions of IV ribavirin were overdose.
The annual prevalence of IV ribavirin users decreased from 1.72% in 2010 to 0.24% in 2017 ($P < 0.001$). A general decrease of prevalence of IV ribavirin were found in different levels of hospitals. For different diagnoses, the prevalence of IV ribavirin decreased with fluctuation. Several factors may have contributed to the decrease of IV ribavirin use: First,
complying with the hospital administration of prescription comment released by the National Health Commission in 2010 (27, 28), prescription evaluation and feedback for improvement by pharmacists can promote the rational use of drugs. Second, the government suggests that medical staff should pay attention to its reproductive toxicity, hemolytic anemia, and other safety issues (29).

Up to now, because of limited data on human pregnancy exposures to ribavirin, there is not enough evidence of embryotoxicity and teratogenicity of ribavirin in humans. A ribavirin pregnancy registry has been established and operated since 2003 in the United States (30). It monitors maternal-fetal outcomes of pregnant women or female partners of male patients exposed to ribavirin. The primary purpose of the registry is to evaluate the association between teratogenic risk and ribavirin exposures during pregnancy or within 6 months after treatment is stopped. Exposure may be incurred directly, when the pregnant female takes ribavirin, or indirectly, when her male sexual partner is treated with ribavirin. For registry purposes, exposure is defined as direct or indirect exposure to ribavirin during pregnancy or within the 6 months before pregnancy. Using data collected from 2003 to February 2016 in this registry study, preliminary findings do not indicate a clear signal of human teratogenicity for ribavirin (31). However, it is insufficient to draw the definitive conclusions under the current limited sample size. Despite this, patients and physicians should be aware of the potential teratogenicity of ribavirin and follow the instructions. Since there is no such pregnancy registry in China, we suggest to further investigate the risk of ribavirin among pregnant women by using linked database of birth registry and electronic medical records.

**STRENGTHS AND LIMITATIONS**

Our study had several strengths. First, our study was the first to investigate the utilization of intravenous ribavirin among adults aged 18–44 in China by using a regional healthcare database in a real-world context. Second, exposure of IV ribavirin using prescription records had the advantage of avoiding recall bias. Third, the data on the demographic characteristics, hospital level, diagnosis, and prescription dosage were available, so we can delineate the prevalence across different subpopulations. Finally, these data provided a cohort which can be followed longitudinally for further investigations of safety and risk-benefit of treatment with IV ribavirin.

Limitations should be acknowledged in the interpretation of our findings. First, since our study relied on a regional healthcare database, it only covered the population of Yinzhou district of the Ningbo city which is located at eastern China, thus interpretation and extrapolation should be made cautiously. Although the cohort is geographically limited, it comprises nearly fifty thousand patients exposed to IV ribavirin in different levels of hospital which is the largest study of ribavirin use to date that we are aware of. Second, this was a descriptive study and clinical data such as laboratory results, symptoms, and prescriber qualification in the database for the drug use were not assessed.
CONCLUSION

In conclusion, this study is an electronic medical records based study to investigate the utilization of intravenous ribavirin in China from 2010 to 2017. Our findings demonstrate the high prevalence of exposure to intravenous ribavirin in Chinese childbearing-aged population, compared to United States, especially among elder patients, or patients with low level of education and income, or in primary hospitals. Although the annual prevalence was decreasing over past 8 years, clinicians and pharmacists should continually avoid inappropriate use of IV ribavirin. Furthermore, we found IV ribavirin were mainly used for acute respiratory infection suggesting that large amount of IV ribavirin use were inappropriate because most of the acute respiratory infection were not caused by RSV. Given these findings, together with the limited research on the safety and effectiveness of treatment with IV ribavirin, future research is needed. This study provides a cohort with a large population and comprehensive medical records for further researches on the safety and effectiveness of IV ribavirin use.

DATA AVAILABILITY STATEMENT

The data analyzed in this study is subject to the following licenses/restrictions: Data can only be used locally. Requests to access these datasets should be directed to Hongbo Lin, lin673160@163.com.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Peking University Health Science Center Institutional Review Board. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

HL and SZ: contributed to the study conception and design. HL and HZ: analyzed the data and drafted the manuscript. HLin, PS, and CL: critically revised the manuscript. All authors were involved in interpretation of data, read, and approved the final manuscript.

FUNDING

This study was supported by the National Natural Science Foundation of China (81973146 and 72004151).

ACKNOWLEDGMENTS

We thank the Health and Family Planning Bureau of Yinzhou District for authorizing the use of EMR and also thank Centers for Disease Control for providing access to the databases used in the study. We also thank Dr. Bing Guo (Department of Epidemiology and Health Statistics, West China School of Public Health, Sichuan University) for reviewing and giving suggestions on improving this article.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh. 2021.678785/full#supplementary-material

REFERENCES

1. Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol. (2006) 16:37–48. doi: 10.1002/rmv.483
2. Riner A, Chan-Tack KM, Murray JS. Original research: intravenous ribavirin—review of the FDA’s emergency investigational new drug database (1997-2008) and literature review. Postgrad Med. (2009) 121:341–6. doi: 10.3810/pgm.2009.05.2014
3. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. (2007) 11:1–205, iii. doi: 10.3310/hta11110
4. Shahangian S, Labeau KM, Howerton DA. Prothrombin time testing practices: adherence to guidelines and standards. Clin Chem. (2006) 52:793–4. doi: 10.1373/clinchem.2005.065433
5. Ovbiagele B, Saver JL, Bang H, Chambless LE, Nassief A, Minuk J, et al. Statin treatment and adherence to national cholesterol guidelines after ischemic stroke. Neurology. (2006) 66:1164–70. doi: 10.1212/01.wnl.0000208403.18885.0e
6. Desalu I, Kushimo O, Akinlaja O. Adherence to CPR guidelines during perioperative cardiac arrest in a developing country. Resuscitation. (2006) 69:517–20. doi: 10.1016/j.resuscitation.2005.01.012
7. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, Soler-Soler J. Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surgery. J Am Coll Cardiol. (2006) 47:1012–7. doi: 10.1016/j.jacc.2005.10.049
8. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. (2007) 1:CD000181. doi: 10.1002/14651858.CD000181.pub3
9. Xiang Z, Gonzalez R, Ren L, Xiao Y, Chen L, Zhang J, et al. Prevalence and clinical characteristics of human respiratory syncytial virus in Chinese adults with acute respiratory tract infection. J Med Virol. (2013) 85:43–53. doi: 10.1002/jmv.23467
10. O’Shea MK, Pipkin C, Cane PA, Gray GC. Respiratory syncytial virus: an important cause of acute respiratory illness among young adults undergoing military training. Influenza Other Respi Viruses. (2007) 1:193–7. doi: 10.1111/j.1750-2659.2007.00029.x
11. Schappveld M, de Vries EG, Otter R, de Vries J, Dolsma WV, Willems PH. Guideline adherence for early breast cancer before and after introduction of the sentinel node biopsy. Br J Cancer. (2005) 93:520–8. doi: 10.1038/sj.bjc.6602747
12. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis. (1999) 19(Suppl. 1):17–24.
13. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol. (2006) 62:710–4. doi: 10.1111/j.1365-2125.2006.02714.x
14. Grubb RL, Roehl KA, Antenor JA, Catalona WJ. Results of compliance with prostate cancer screening guidelines. J Urol. (2005) 174:668–72; discussion 72. doi: 10.1097/01.ju.0000165149.66186.23
15. Millen BE, Quatromoni PA, Nam BH, Pencina MJ, Polak JF, Kimokoti RW, et al. Compliance with expert population-based dietary guidelines and lower
16. Wang JB, Gu MJ, Shen P, Huang QC, Bao CZ, Ye ZH, et al. Body mass index and mortality: a 10-year prospective study in China. Sci Rep-Uk. (2016) 6:1609. doi: 10.1038/srep1609

17. Zhao M, Lin HB, Yuan YY, Wang FY, Xi Y, Wen LM, et al. Prevalence of pre-diabetes and its associated risk factors in rural areas of Ningbo, China. Int J Env Res Pub He. (2016) 13:808. doi: 10.3390/ijerph13080808

18. Yang Y, Zhou XF, Gao SQ, Lin HB, Xie YM, Feng YJ, et al. Evaluation of electronic healthcare databases for post-marketing drug safety surveillance and pharmacoepidemiology in China. Drug Safety. (2018) 41:125–37. doi: 10.1007/s40264-017-0589-z

19. Li H, Lin H, Zhao H, Xu Y, Cheng Y, Shen P, et al. Statins use and risk of new-onset diabetes in hypertensive patients: a population-based retrospective cohort study in Yinzhou district, Ningbo city, People’s Republic of China. Ther Clin Risk Manag. (2018) 14:823–32. doi: 10.2147/TCRM.S158880

20. Lin H, Tang X, Shen P, Zhang D, Wu J, Zhang J, et al. Using big data to improve cardiovascular care and outcomes in China: a protocol for the CHinese Electronic health Records Research in Yinzhou (CHERRY) Study. BMJ Open. (2018) 8:e019689. doi: 10.1136/bmjopen-2017-019689

21. Yuan SY. China should reduce the overuse of intravenous infusion. Bmj-Brit Med J. (2014) 348:g1262. doi: 10.1136/bmj.g1262

22. Kan J, Zhu XX, Wang TY, Lu RZ, Spencer PS. Chinese patient demand for intravenous therapy: a preliminary survey. Lancet. (2015) 386:61. doi: 10.1016/S0140-6736(15)00642-X

23. Avalos LA, Chen H, Yang C, Andrade SE, Cooper WO, Cheetham CT, et al. The prevalence and trends of antiviral medication use during pregnancy in the US: a population-based study of 664,297 deliveries in 2001-2007. Matern Child Health J. (2014) 18:64–72. doi: 10.1007/s10995-013-1234-9

24. Rusnak JM, Byrne WR, Chung KN, Gibbs PH, Kim TT, Boudreau EF, et al. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res. (2009) 81:68–76. doi: 10.1016/j.antiviral.2008.09.007

25. Huggins JW, Hsiang CM, Cosgroff TM, Guang MY, Smith JJ, Wu ZO, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. (1991) 164:1119–27. doi: 10.1093/infdis/164.6.1119

26. Muller MP, Dresser L, Raboud J, McGeer A, Rea E, Richardson SE, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy. (2007) 27:494–503. doi: 10.1592/phco.27.4.494

27. Wei X, Yin J, Walley JD, Zhang Z, Hicks JP, Zhou Y, et al. Impact of China’s essential medicines scheme and zero-mark-up policy on antibiotic prescriptions in county hospitals: a mixed methods study. Trop Med Int Health. (2017) 22:1166–74. doi: 10.1111/tmi.12922

28. Song Y, Bian Y, Petzold M, Li L, Yin A. The impact of China’s national essential medicine system on improving rational drug use in primary health care facilities: an empirical study in four provinces. BMC Health Serv Res. (2014) 14:507. doi: 10.1186/s12913-014-0507-3

29. Law A, Chan KL. Surgical referral in symptomatic mitral regurgitation: greater compliance with guidelines is needed. Eur Heart J. (2007) 28:1281–2. doi: 10.1093/eurheartj/ehm156

30. Roberts SS. Assessing ribavirin exposure during pregnancy the ribavirin pregnancy registry. Gastroenterol Nurs. (2008) 31:413–7. doi: 10.1097/SGA.0b013e318181eb70d

31. Sinclair SM, Jones JK, Miller RK, Greene MF, Kwoo PY, Maddrey WC. The Ribavirin pregnancy registry: an interim analysis of potential teratogenicity at the mid-point of enrollment. Drug Safety. (2017) 40:1205–18. doi: 10.1007/s40264-017-0566-6

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Li, Zhao, Lin, Shen, Liu and Zhan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.